Skip to main content

Motor Neuron Disease clinical trials at UC Health
3 research studies open to new patients

  • AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)

    open to eligible people ages 18-80

    The CENTAUR trial will be a 2:1 (active:placebo) randomized, double-blind, placebo-controlled Phase II trial to evaluate the safety and efficacy of AMX0035 for the treatment of ALS.

    at UC Irvine

  • Answer ALS: Individualized Initiative for ALS Discovery

    open to eligible people ages 18-100

    Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples (blood and spinal fluid (optional)), and cell lines for ALS gene identification. This will be combined carefully with collected measures of the pattern of the symptoms people with ALS have and how these change over time. People with other motor neuron diseases and healthy controls will be included as comparisons

    at UC Irvine

  • Deep Phenotyping in Patients With ALS

    open to eligible people ages 18-75

    This study aims to establish a biorepository and phenotyping database to investigate longitudinal changes in ALS subjects. Blood, including DNA and RNA, cerebrospinal fluid (CSF) and electrophysiologic measures will be collected every 3 months over 1 year. The database and specimen repository will be made available to ALS researchers on a merit basis.

    at UC Irvine

Last updated: